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SUMMARY 
Im Rahmen traumatischer Rückenmarkverletzungen kommt es regelmäßig zu schweren und 
permanenten neurologischen Funktionsstörungen bzw. -ausfällen. Der irreversible Verlust 
ortsständiger Rückenmarkzellen einschließlich Neuronen, Astrozyten und Oligodendrozyten 
sowie die damit einhergehenden ausgeprägten strukturellen Veränderungen repräsentieren das 
morphologische Korrelat für die schweren funktionellen Beeinträchtigungen. Da das 
Rückenmark die Hauptverbindung zwischen dem peripheren Nervensystem und den 
Steuerungszentren des Zentralnervensystems (ZNS) darstellt, führen Verletzungen in 
unterschiedlichem Ausmaß zu sensiblen, motorischen sowie autonomen neurologischen 
Ausfällen. Auch bei schwersten Schädigungen des Rückenmarks bleibt bei einem Großteil 
der Patienten ein Teil der aufsteigenden bzw. absteigenden Axone erhalten. Allerdings kommt 
es häufig zur Demyelinisierung der verbliebenen Axone, so dass diese nicht zu einer 
möglichen funktionellen Erholung beitragen können. Obwohl spontan oligodendroglialer 
Zellersatz stattfindet, ist das adulte Rückenmark nicht in der Lage, den im Rahmen einer 
traumatischen Schädigung aufgetretenen Zelluntergang suffizient auszugleichen. Aus diesem 
Grund wird intensiv nach adäquaten Zellersatzstrategien gesucht. Stammzellen stellen hierfür 
einen vielversprechenden Therapieansatz dar. 
Kürzlich konnte gezeigt werden, dass mesenchymale Stammzellen (MSC) einen bislang 
unbekannten Faktor sezernieren, welcher unter Ko-Kulturbedingungen die oligodendrogliale 
Differenzierung von adulten neuralen Vorläuferzellen aus dem Hippocampus sowie der 
Subventrikulärzone fördert und gleichzeitig die astrogliale Differenzierung dieser neuralen 
Vorläuferzellen inhibiert. In der vorliegenden Studie wurde zunächst der Einfluss von 
konditioniertem Medium der MSC (MSC-CM) auf das Differenzierungsverhalten von adulten 
neuralen Vorläuferzellen aus verschiedenen anatomischen ZNS-Regionen 
(Subventrikulärzone, Hippocampus, Rückenmark) unter Zellkulturbedingungen untersucht. 
Der vorbeschriebene prooligodendrogliale Effekt in Anwesenheit von MSC-CM konnte 
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erstmals auch in neuralen Vorläuferzellen aus dem Rückenmark sowie der subventrikulären 
Zone nachgewiesen werden. Im direkten Vergleich der einzelnen ZNS-Regionen bezüglich 
des Ausmaßes der Oligodendrogliogenese ergaben sich keine signifikanten Unterschiede. 
Im Anschluss daran wurden die Effekte von MSC-Transplantaten auf die endogene 
Oligodendrogliogenese unmittelbar nach einer akuten traumatischen Rückenmarkverletzung 
analysiert. Im Vergleich zu Kontrolltieren, welche lediglich eine Rückenmarkläsion ohne 
Transplantat erhalten haben, steigern MSC-Transplantate das Ausmaß oligodendroglialer 
Differenzierung im Bereich der Rückenmarkläsion. Die gesteigerte oligodendrogliale 
Differenzierung ging, wie auch in vitro gezeigt, auf Kosten der astroglialen Differenzierung, 
die im Vergleich zu Kontrolltieren signifikant reduziert war. Die Ergebnisse der in-vitro 
Versuche legen die Vermutung nahe, dass diesem prooligodendroglialen Effekt ein von den 
MSC sezernierter löslicher Faktor als ursächlicher Mechanismus zugrunde liegt. Die exakte 
Identifizierung dieses Faktors ist im Hinblick auf ein genaueres Verständnis der Interaktionen 
zwischen MSC und endogenen neuralen Rückenmarkstammzellen von großer Bedeutung. 
Darüber hinaus müssen weiterführende Studien zeigen, ob die auf diese Weise neu 
entstandenen Oligodendrozyten in der Lage sind, die von der initialen Verletzung 
ausgesparten Axone zu remyelinisieren und dadurch zu einer funktionellen Erholung 
beitragen.  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1. INTRODUCTION 
1.1. Spinal cord injury 
Spinal cord injury (SCI) regularly leads to severe and permanent disability. In most cases it is 
caused by a trauma resulting in vertebral fracturing with dislocation of bone fragments and 
consecutive contusion of spinal cord tissue. As the spinal cord represents the exclusive nerve 
conduction path between higher order brain structures and the peripheral nervous system, 
these injuries result in severe impairment of motor, sensory and autonomic function below the 
lesion site. Depending on the level and severity of injury, functional recovery can be 
achieved1.  
In patients with partial preservation of ascending and descending axon pathways across the 
lesion (incomplete SCI) limited spontaneous functional recovery is observed2. However, in 
more severe cases sensory, motor and autonomous function below the spinal cord lesion level 
is completely abolished (complete SCI). Effective regenerative therapies are not yet 
established. Interestingly, post mortem studies in subjects with functionally complete SCI 
revealed that despite complete loss of function a rim of still intact axon pathways across the 
lesion site is regularly observed1,3,4. However, the majority of preserved axons are 
demyelinated, which prevents proper nerve conduction and functional recovery. Therefore, 
therapeutic strategies aiming for remyelination of preserved axons might be able to promote 
partial functional recovery.  
 
1.1.1. Epidemiology 
The incidence of traumatic SCI worldwide varies between 12.1 to 57.8 cases per 1 million 
inhabitants in Western Europe respectively 25.2 to 52.5 in North America5. Lower incidence 
rates have been found in developing countries (12.7 to 29.7 per million inhabitants)6. 
Prevalence rates have shown a wide range from 130 up to 1124 per 1 million7. Common 
causes of traumatic SCI are motor vehicle accidents (42,1%), falls (26,7%; primary cause in 
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patients older 60 years), violence (15,1%) and sports activities (7,6%)8. The most common 
site of injury is the cervical spinal cord (around 54%), followed by thoracic (24%), lumbar 
(19%) and sacral (1%) spinal cord lesions5. In traumatic SCI studies two age peaks between 
15 to 29 years and around 65 and older are observed5. The average age of patients suffering a 
SCI is around 33 years with a clear preference for males (2:1 to 7:1)9,10,11. However, there is a 
strong trend towards older individuals suffering from SCI within the last decade.  
 
1.1.2. Classification of spinal cord injury 
According to the American Spinal Injury Association Impairment Scale (ASIA) spinal cord 
injuries can be classified into 5 categories (ASIA A – E). ASIA A (45%) represents a 
functionally complete SCI with total loss of sensory and motor function below the level of 
injury. Incomplete spinal cord injuries start with ASIA B, being sensory incomplete but motor 
complete, all the way up to ASIA E. Each step (C, D, E) is characterized by an increasing 
motor score below the level of injury. Over the last decades injury severity shifted towards 
incomplete injuries, which account nowadays for almost two thirds of all traumatic spinal 
cord injuries7,12. 
 
1.1.3. Signs and symptoms of spinal cord injury  
The clinical manifestation of SCI depends in particular on the level of injury. Cervical spinal 
cord lesions result in varying degrees of paresis and sensory impairment in the upper and 
lower extremities (tetraparesis or tetraplegia), whereas thoracic and lumbar lesions affect the 
trunk and lower extremities (paraparesis, paraplegia). Lesions at sacral level frequently affect 
exclusively bowel and bladder function. The interruption of the autonomic nervous system, 
which can happen at any level almost always causes neurogenic bladder and bowel 
dysfunction. In particular, cervical and high thoracic lesions are accompanied by 
cardiovascular dysfunction, so called autonomic dysregulation or autonomic dysreflexia.  
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In terms of mortality, the level of injury and the age of the patient at the time of injury are the 
most important factors7. The higher the lesion level, the lower the survival rate13. Patients 
with tetraplegia as a result of a cervical SCI are reported to have an almost  
7-times higher mortality rate compared to patients with paraplegia. In terms of functional 
recovery, the level of incompleteness determines the respective prognosis. Less than 10% of 
SCI patients classified as ASIA A recover gait and standing function, whereas this rate 
increases dramatically in ASIA B, C and D patients14. 
 
1.1.4. Current concepts of spinal cord injury treatment 
Established treatment of acute traumatic SCI consists of conservative and surgical (spine 
stabilization, decompression) measures including continuous monitoring on the intensive care 
unit to prevent cardiovascular, pulmonal and gastrointestinal complications. To compensate 
for lost function, to regain as much neurological function and to prevent secondary 
complications, neurorehabilitation in dedicated SCI centers, which provide highly spezialized 
medical and nursing care, physical therapy, occupational therapy, speech therapy, needs to be 
initiated as soon as possible. In particular, control of bowel/bladder/sexual function, spasticity 
and neuropathic pain need to be addressed in all patients with SCI. Up to now there is not a 
single established therapeutic intervention outside neurorehabilitation, which alters the course 
of the disease in a positive fashion. Therefore, regenerative therapies are urgently needed to 
promote recovery of function and quality of life in spinal cord injured subjects15.  
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1.1.5. Pathomechanisms of spinal cord injury 
In general three phases of SCI response can be observed. Acute, secondary and chronic injury 
processes16-20. The initial force (primary injury mechanism) causes immediate damage to the 
neural tissue (neurons, glia, long distance axons) and the vasculature of the spinal cord at the 
lesion level16,21. Subsequently, secondary injury mechanisms such as apoptosis22-24, vascular 
changes21,25-29, inhibition of intracellular protein synthesis, ionic dearrangements30,31, free 
radicals32-34 and glutaminergic excitoxicity35-37 come into play. Immune cells become 
activated or migrate into the lesion to orchestrate an inflammatory reaction. This immune 
response is considered to have both beneficial (e.g. phagocytosis of axon growth inhibiting 
myelin debris38,39 or limitation of secondary tissue damage by modulation of the T-cell 
response40) as well as negative effects (e.g. release of free radicals, enzymes and 
proinflammatory cytokines41-44) on recovery and functional outcome after SCI. In order to 
develop new treatment strategies in the future, it will be necessary to gain a deeper 
understanding of those complex secondary injury mechanisms and their relationship 
following acute SCI7. In the subacute to chronic phase lasting from days to years after the 
initial trauma the neural tissue in the lesioned spinal cord degenerates and a cystic lesion 
cavity surrounded by a fibroglial scar develops45. Apoptosis of oligodendroglia with 
consecutive demyelination of spared axons contributes to the failure of the injured spinal cord 
to recover spontaneously1. 
 
1.1.5.1. Growth inhibitory components and factors affecting intrinsic regenerative 
capacity 
The cystic lesion defect developing within weeks after SCI represents a major obstacle for 
structural restoration following SCI. Neural tissue at the SCI lesion site lost due to necrosis 
and apoptosis is not replaced appropriately leaving a fluid filled cavity behind46. 
Subsequently, the initial cystic defect can further increase by ongoing apoptosis and release of 
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hydrolytic lysosomal enzymes45,47,48. The cystic lesion defect represents a physical barrier, 
which cannot be crossed by regrowing axons. Cell-based regenerative strategies try to 
overcome this barrier by providing a growth conducive environment, which might allow axon 
regeneration and functional recovery49. 
 Lesion defects within the spinal cord are typically sealed off by a scar. This barrier consists 
of cellular and extracellular components. On the cellular side, astroglia and fibroblasts 
represent the main components50,51. Extracellular components such as chondroitin sulfate 
proteoglycans (e.g. neurocan, phosphocan, vesican, NG2 and aggrecan) support the 
scar4,49,52,53,54. Besides its negative effects as an axon growth inhibitory factor the glial scar 
plays an import role in stabilizing injured spinal cord tissue55. The scar supports the repair of 
the blood-brain-barrier, helps to contain the inflammatory response56, protects spared neurons 
and oligodendrocytes by the secretion of growth factors and cytokines57,53. Molecular 
obstacles of regeneration are myelin-based inhibitors such as Nogo, Myelin-Associated 
Glycoprotein (MAG), tenascin-R and Oligodendrocyte Myelin glycoprotein (OMgp), which 
are released by damaged oligodendrocytes at the lesion site58,59.  
Numerous molecular changes have been discovered, which contribute to the intrinsic failure 
of injured central nervous system (CNS) axons to spontaneously regenerate. Neurite growth 
and regeneration associated genes are not upregulated as they should be60-63. Neurotrophic 
factors such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF) and 
neurotrophin-3/-4/5 (NT-3/-4/5), which are essential to maintain neuronal phenotypes and 
sustain synaptic functions during development, can also prevent axotomy induced neuronal 
atrophy after SCI64-68.  
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1.1.5.2. Demyelination 
Demyelination is observed in the course of the initial trauma and as part of secondary 
structural changes4,69. During the acute phase of SCI, necrosis more than apoptosis is 
responsible for cell death (especially within the surrounding grey matter), myelin breakdown 
and the consecutive loss of function in the vicinity of the primary lesion (primary 
demyelination). In addition the accumulation of macrophages and microglia within the 
lesioned area during the acute and subacute injury phase may also have a detrimental effect 
on the survival of damaged cells at the lesion center70. Nevertheless the loss of spinal cord 
cells and neurological function subsists for weeks to month due to secondary injury 
mechanisms (secondary demyelination). Especially myelin-forming oligodendrocytes ruled 
out to be very capable for those secondary degeneration processes20,23,71-74. In a rat spinal cord 
contusion model, Totoui et al. demonstrated that SCI is accompanied by progressive 
demyelination75. Within days to weeks after SCI axonal degeneration and myelin breakdown 
can also be found in long white matter tracts remote from the initial lesion76,77. Most likely 
ongoing apoptosis plays a central role within this process of chronic demyelination after 
SCI78. Especially the long-term apoptotic death of myelin-forming oligodendrocytes in long 
fiber tracts undergoing Wallerian degeneration significantly contributes to demyelination of 
spared axonal pathways remote from the lesion epicenter contributing to permanent 
neurological dysfunction79. These findings have been observed both in experimental SCI in 
small animals such as rats and mice23,80-84 and human SCI19,74, suggesting there might be a 
therapeutic window to protect oligodendroglia and reduce demyelination after SCI in humans.  
 What is the ideal spinal cord injury model to study demyelination and consecutively 
remyelination strategies? A recent study demonstrates that contusion SCI substantially differs 
from transection SCI, resulting in a more widespread initial mechanical trauma, leading to 
apoptosis of oligodendrocytes at greater distances (several millimeters) rostral and caudal 
from the lesion epicenter with consecutive demyelination. Apparently the extent of the initial 
Introduction 
  11 
mechanical injury is highly correlated with the extent of demyelination85. As opposed to 
highly standardized and uniform experimental SCI one has to keep in mind that injury 
mechanisms vary significantly in human SCI, which most likely results in a wide range of 
demyelination extent2. Post mortem studies of injured spinal cords in humans have shown that 
in clinically complete spinal cord injured patients a significant number of spared axons is 
frequently observed (so called anatomically “discomplete”)2,3,77,86. The majority of these 
spared axons are typically demyelinated, which prohibits proper nerve conduction. Thus, 
despite axon sparing preserved pathways are unable to mediate functional recovery85,87,88.  
 
1.1.5.3. Remyelination 
Remyelination is a spontaneous process that follows demyelination69,75,85,89,90. Reports on 
remyelination inside the damaged CNS date back to the 1960s91,92. Over the last decades 
oligodendroglial progenitor cells (OPC) have been identified as the source of CNS 
remyelination93. In terms of remyelination of spared axons it is essential that OPC 
differentiate into mature myelin-forming oligodendrocytes following their recruitment and 
migration from the subependymal layer of the spinal cord central canal towards the lesioned 
area. This process encompasses a couple of steps: First a contact with the demyelinated axon 
has to be established, followed by the expression of myelin genes and the generation of 
myelin membranes, and finally wrapping and compacting those membranes to ultimately 
form the myelin sheat94. Interestingly several experimental models of chemically-induced 
demyelination resulted in complete remyelination by endogenous progenitor cells85,95-97. 
However, there is only poor remyelination after SCI leaving permanently demyelinated axons 
behind69,75,90.  
A lack or deficiency in precursor cells, a failure of precursor cell recruitment and a failure of 
precursor cell differentiation and maturation have been identified as reasons for poor 
remyelination. In particular, insufficient terminal oligodendroglial differentiation appears as 
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the most relevant factor, which prevents the formation of myelin and consecutive restoration 
of nerve conduction94. These findings are based on the detection of oligodendroglial lineage 
cells that are apparently unable to fully differentiate in areas of demyelination98,99. As 
underlying mechanism for the insufficient oligodendroglial differentiaton several factors have 
been identified. Especially the expression of myelin-associated proteins after SCI inhibits 
terminal differentiation into fully myelinating oligodendroglia100-102. 
Taken together, the extent of demyelination and insufficient endogenous remyelination shown 
in experimental SCI provide a relevant target for regenerative therapeutic interventions. 
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1.2. Regenerative strategies after spinal cord injury 
Strategies to promote structural regeneration following SCI include axonal repair, neuronal 
replacement and remyelination strategies2,3,77,103,104. The following chapter will address these 
different repair strategies in more detail. 
 
1.2.1. Axonal repair 
The breakdown of communication between the peripheral nervous system and the brain is 
mainly caused by the interruption of long ascending (sensory) and descending (motor) axonal 
pathways105. It has been shown that recovery after SCI is significantly correlated with the 
amount of surviving axons106,107. Therefore, strategies to promote axonal plasticity and 
regeneration represent the prime target for innovative therapeutic concepts1,3,4. Various 
neurotrophic factors have been shown to enhance spinal cord plasticity and axonal outgrowth 
so far (e.g. the upregulation of neurite growth and regeneration associated genes)60-63,65-67,108-
113. Neutralization of molecules inhibiting axonal regeneration such as CSPG (chondroitin 
sulfate proteoglycans) and myelin-based inhibitors represents another strategy to elicit axon 
repair114-124.  
The injured adult mammalian spinal cord parenchyma is unable to replace lost tissue in a 
phenotypically appropriate fashion. Therefore, efficient cell/tissue replacement strategies at 
the lesion site are required to promote axon regeneration with consecutive functional repair 
after SCI. Both, cell and biomaterial based transplantation/implantation therapies are effective 
to promote axon regrowth/sprouting to a limited extent1,49,52,125-129. 
 
1.2.2. Strategies for remyelination 
SCI results in loss of oligodendrocytes, demyelination of spared axons and severe functional 
impairment. Since the adult CNS provides only a very limited capacity for spontaneous 
remyelination (especially since the terminal differentiation of endogenous progenitor cells 
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into mature myelin-forming oligodendrocytes is often not sufficient), cell transplantation 
strategies are an attractive approach for myelin repair. Very encouraging results originate 
from two major therapeutic approaches: 1) transplantation of cells with the potential to 
myelinate spared axons 2) stimulation of endogenous spinal cord progenitor cells to 
differentiate into mature myelin-forming oligodendrocytes. 
 
1.2.2.1. Transplantation of myelin-forming cells 
Several cell types have been transplanted to the lesioned spinal cord to extrinsically replace 
myelin-forming cells. Neural stem cells can differentiate into oligodendrocytes, which are 
capable to remyelinate axons. However, in most instances spontaneous differentiation into 
mature oligodendroglia is sparse130,131. A variety of strategies has been employed to enhance 
oligodendroglial differentiation of grafted neural stem/progenitor cells such as the 
administration of growth factors132, the manipulation of gene expression or co-grafting of 
other cell types108,133-138.  
Neural stem cell transplantation approaches either alone or in combination with growth 
factors induced limited remyelination and functional recovery in small animal models of 
SCI128.  
Outside of the CNS Schwann cells represent the only other cell type which forms myelin. 
Interestingly the formation of myelin by Schwann cells is not limited to the peripheral 
nervous system only, but can also be observed in the CNS following invasion or grafting of 
Schwann cells to the injured spinal cord. Numerous studies revealed their potential to form 
functionally relevant myelin-sheets with improvement of saltatory nerve conduction velocity 
after transplantation to different CNS areas including the spinal cord133,139,140. Similar results 
have been published with olfactory ensheating cells141-144, which can be considered as a 
hybrid cell between peripheral nervous system (Schwann cell) and CNS (astrocytes) glia. 
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1.2.2.2. Stimulation of endogenous progenitor cells for remyelination 
Various studies have focused on maximizing the regenerative potential of endogenous neural 
progenitor cells (NPC) in the spinal cord by stimulating their recruitment, proliferation, 
migration and differentiation to intrinsically restore lost tissue following SCI1,145. 
The creation of a microenvironment conducive to regeneration by endogenous spinal cord 
stem cells with consecutive remyelination of spared axons plays a central role in this 
remyelination strategy. This goal could be achieved by local changes at the lesion site, 
probably mediated indirectly by the production of growth factors, cytokines, neurotrophic 
factors, favorable substances for axonal growth, effects on vasculature and other promoters of 
neurological recovery1,94,146. 
Recently, mesenchymal stem cells (MSC) have been shown to secrete soluble factors, which 
strongly promote oligodendroglial fate decision in adult NPC derived from the hippocampus 
(HC) or the subventricular zone (SVZ) in vitro. The shift of differentiation towards the 
oligodendroglial lineage has been demonstrated by a highly significant increase of the 
oligodendroglial markers MBP (myelin basic protein) and GalC (galactocerebroside) at the 
expense of astrogenesis, which was confirmed by a reduction of newborn  
GFAP-expressing astrocytes (glial fibrillary acidic protein). Subsequent experiments showed 
that enhanced oligodendroglial differentiation can be recapitulated on postnatal hippocampal 
slices cultures, which were incubated with MSC and NPC138,147,148. The exact factor to exert 
remyelination has yet to be identified149. 
Therefore, the transplantation of MSC or administration of MSC-CM (mesenchymal stem cell 
– conditioned medium) might also have the capacity to promote oligodendroglial 
differentiation in vivo. However MSC failed to enhance oligodendroglial differentiation of 
co-grafted exogenous NPC after transplantation to the acutely injured rat spinal cord137,138.  
The aim of the present study is to investigate whether pure MSC grafts will promote 
oligodendroglial differentiation in endogenous glial progenitor cells after spinal cord injury. 
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2. AIM OF THE THESIS 
The aim of the thesis project is to investigate whether MSC grafted into the injured rat spinal 
cord will promote oligodendroglial differentiation in endogenous glial progenitor cells as 
prerequesite for enhanced remyelination. 
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3. MATERIAL & METHODS 
3.1.Chemicals & Materials 
3.1.1. Cell culture 
Chemicals Source 
Alpha-MEM Gibco BRL, Germany 
Accutase PAA Laboratories, Linz, Austria 
Acepromazine  Sanofi-Ceva, Düsseldorf, Germany 
B27 supplement Gibco BRL, Germany 
Boric acid Sigma-Aldrich, Taufkirchen, Germany 
Bromodesoxyuridine (BrdU) Sigma-Aldrich, Taufkirchen, Germany 
Dispase II Boehringer, Germany 
DMEM/F12 PAN Biotech GmbH, Aidenbach, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
DNase I Worthington Biochemicals, England 
Dulbecco´s phosphate buffered saline 
(DPBS) PAA Laboratories, Linz, Austria 
Epidermal growth factor (EGF) R&D Systems, Germany 
Fetal bovine serum (FBS) PAN Biotech GmbH, Aidenbach, Germany 
Fibroblast growth factor (FGF) R&D Systems, Germany 
G418 (geneticin) Invitrogen / Gibco, Karlsruhe, Germany 
Glucose Merck, Germany 
Hank´s Balanced Salt Solution (HBSS) PAA Laboratories, Linz, Austria 
Heparin Sigma-Aldrich, Taufkirchen, Germany 
Ketamine WDT, Garbsen, Germany 
Laminin Sigma-Aldrich, Taufkirchen, Germany 
L-glutamine PAN Biotech GmbH, Aidenbach, Germany 
NaH2PO4 Sigma-Aldrich, Taufkirchen, Germany Na2HPO4 Sigma-Aldrich, Taufkirchen, Germany 
Neurobasal medium (NB) Gibco BRL, Germany 
Papain Worthington Biochemicals, England 
Penicillin/streptomycin PAN Biotech GmbH, Aidenbach, Germany 
Polybrene (hexadimethrine bromide) Sigma-Aldrich, Taufkirchen, Germany 
Poly-L-ornithine Sigma-Aldrich, Taufkirchen, Germany 
Sodium hydroxide (NaOH) Sigma-Aldrich, Taufkirchen, Germany 
Trypan blue Sigma-Aldrich, Taufkirchen, Germany 
Trypsin Gibco BRL, Germany  
 
3.1.2. Immunodetection 
Chemicals Source 
3,3´-Diaminobenzidine (DAB)  Vector Laboratories, Burlingame, USA 
4,6´-Diamidino-2-phenylindole (DAPI) Sigma-Aldrich, Taufkirchen, Germany 
Bovine serum albumin (BSA) Biomol, Germany 
DAB Peroxidase Substrate Kit Biozol, Eching, Germany 
Donkey serum PAN Biotech GmbH, Aidenbach, Germany 
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Gelatine from cold water fish skin Sigma-Aldrich, Taufkirchen, Germany 
Prolong Antifade Invitrogen GmbH, Germany 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
Vectastain Elite ABC kit  Vector Laboratories, Burlingame, USA 
Xylazine WDT, Garbsen, Germany 
 
3.1.3. Other Chemicals + Kits 
Chemicals Source 
Ethanol Baker, Unterschleißheim, Germany 
2-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
2-Methylbutane Fluka 
Paraformaldehyde Sigma-Aldrich, Taufkirchen, Germany 
 
3.1.4. Antibodies 
Primary antibody Dilution Source 
ms α APC (adenomatous polyposis 
coli) 1:500 Calbiochemi, Darmstadt, Germany 
rt α BrdU (Bromodesoxyuridine) 1:500 AbDSerotec, UK 
rb α GFAP  
(glial fibrillary acidic protein) 1:1000 Dako, A/S, Glostrup, DK 
gt α GFP (green fluorescent protein) 1:500 Rockland, Gilbertsville, USA 
ms α Map2ab  
(microtuble associated protein 2ab) 1:250 Sigma-Aldrich, Taufkirchen, Germany 
ms α MBP (myelin basic protein) 1:750 HiSS Diagnostics GmbH, Germany 
 
Secondary antibody Dilution Source 
dk α ms IgG Alexa Fluor 488 1:1000 Molecular Probes, Germany 
dk α gt IgG Alexa Fluor 488 1:1000 Molecular Probes, Germany 
dk α rb IgG Alexa Fluor 488 1:1000 Molecular Probes, Germany 
dk α ms-RHOX (rhodamine X) 1:500 Dianova, Hamburg, Germany 
dk α rb-RHOX 1:500 Dianova, Hamburg, Germany 
dk α rt-RHOX 1:500 Dianova, Hamburg, Germany 
dk α rb-CY5 1:500 Dianova, Hamburg, Germany 
dk α rt-Biotin 1:500 Dianova, Hamburg, Germany 
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3.1.5. Buffer and solutions 
Reagent Application 
Borate buffer (0,1M; pH 8.5) 
- 3.08g boric acid 
- 450ml H2O 
- 5M NaOH to pH 8.5 
- fill up to 500ml 
 -  
Cryoprotect solution (CPS) 
- 250ml Glycerine 
- 500ml 0,1M PO4 buffer 
- 250ml ethylene glycol 
 -  
Donkey serum blocking buffer 
- 960µl TBS 
- 30µl donkey serum 
- 10µl Triton X-100 
 -  
Fish skin gelatine buffer (FSGB) 
- 1000ml TBS 
- 10g bovine serum albumin (BSA) 
- 2ml Fish skin gelatine 
- optional: 1ml Triton X-100 
 -  
Phosphate buffer (PO4 0,2M) - 6.35g NaH2PO4 x H2O - 41.35g Na2HPO4 x 7 H2O 
- fill up with ddH2O to 1L 
 -  
Paraformaldehyde 4% (PFA) 
- 40g paraformaldehyde 
- add 500ml H2O 
- heat to 70°C 
- dissolve while stirring 
- add 1ml 10M NaOH 
- filter solution and add 500ml 0.2M PO4 
 -  
Phosphate buffered saline 0,1M (PBS) 
- 500ml 0,2M phosphate buffer 
- 500ml dH2O 
- 9g sodiumchloride 
 -  
PPD (100ml) 
- 0.01% Papain 
- 0.1% Dispase II 
- 0.01% DNase 
- 149mg MgSO4 x 7 H2O 
- in HBSS w/o Ca2+/Mg2+ 
 -  
Sucrose 30% 
- 300g Sucrose 
- 400ml 0,2M PO4 
- 400ml ddH2O 
 -  
20 x SCC 
- NaCl 175.3g 
- 88.2g Trisodium citrate x 2 H2O 
- fill up with dH2O to 1L 
 -  
10 x TBS (Tris buffered saline) 
- Trizma Base 30g 
- KCl 2g 
- NaCl 80g 
- fill up to 1L with dH2O 
- adjust pH 7.4 with 1M HCl  
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3.1.6. Consumables 
Materials Source 
Coverslips and slides VWR International 
Cell culture articles Peske, Aindlingen-Arnhofen, Germany Corning Costar, Germany 
Cell culture media PAN Biotech GmbH, Aidenbach, Germany Invitrogen / Gibco, Karlsruhe, Germany 
Growth factors R&D Systems, Germany 
Gelfoam (Gelita tampon) Braun, Germany 
 
3.1.7. Software 
Program Software producer 
Adobe Illustrator CS3 Adobe, San Jose, USA 
Adobe Photoshop CS3 Adobe, San Jose, USA 
EndNote X3 Thomson Reuters, USA 
Microsoft Office 2008 for Mac OS X  
(12.2.5) Microsoft Corporation, USA 
Prism 4 (Version 4.0a for Macintosh) GraphPad Software, San Diego, USA 
Spot 3.5.9 for Mac OS Diagnostic Instruments, Sterling Heights, USA 
Leica confocal software Leica, Wetzlar, Germany 
 
3.1.8. Equipment and instruments 
Apparatus Source 
Hera Cell incubator Heraeus, Germany 
Hera Safe cell culture hood Heraeus, Germany 
Stereotactic unit Kopf Instruments, Tujunga, USA 
Tungsten wire knife Kopf Instruments, Tujunga, USA 
Picospritzer Π General Valve, Fairfield, USA 
Inverse fluorescence microscope  
for cell culture 
Olympus, Germany 
Leica confacal fluorescence microscope 
(TCS-NT) 
Leica, Wetzlar, Germany 
Leica fluorescent microscope equipped  
with a Spot CCD camera model 2.2.1 
Leica, Wetzlar, Germany 
Diagnostic Instruments, Sterling Heights, USA 
FACSAria Becton Dickinson, USA 
Refrigerated table centrifuge Eppendorf, Hamburg, Germany 
Table centrifuge mini spin plus Eppendorf, Hamburg, Germany 
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3.2. Methods 
3.2.1. Animal subjects 
For all experiments, adult female Fischer 344 rats (Charles River Deutschland GmbH, 
Sulzfeld, Germany) weighing between 160-180g (3-4 months old) were used as donors for 
isolation of NPC, MSC and fibroblasts (FF) as well as for transplantation experiments. All 
experiments were carried out in accordance with the European Communities Council 
Directive (86/609/EEC) and institutional guidelines. Animals had ad libidium access to food 
and water throughout the study. All efforts were made to minimize the number of animals and 
their suffering.  
 
3.2.2. Preparation and cell culture 
3.2.2.1. Preparation of neural progenitor cells (NPC) 
For isolation of the different cell types, adult female Fischer-344 rats were deeply 
anesthetized using a mixture of ketamine (62.5 mg/kg), xylazine (3.175 mg/kg) and 
acepromazine (0.625 mg/kg) in 0.9% sterile saline solution and killed by decapitation. Brains 
and spinal cords were removed and put into Dulbecco´s phosphate buffered saline (DPBS) at 
4°C. Overlying meninges and blood vessels were removed. The HC and the ependymal zones, 
including subependymal and subventricular zones from the lateral wall of the lateral ventricle 
(SVZ), were aseptically removed. The dissected tissue was transferred to fresh DPBS, washed 
once, afterwards transferred to Petri dishes and dissociated mechanically. The cell suspension 
was washed in DPBS to rinse of excess of blood and further digested in PPD solution 
containing 0.01% papain, 0.1% dispase II, 0.01% DNase I and 12.4 mMgSO4, dissolved in 
Hank´s balanced salt solution (HBSS) for 30 min at 37°C. Thereafter the cell suspension was 
triturated every 10 min until the tissue was digested completely. The tissue was centrifuged at 
120 x g for 5 min at 4°C and washed three times in Neurobasal (NB) medium supplemented 
with B27, 2 mM L-glutamine, 100 U/ml penicillin / 0.1 mg/l streptomycin. Cells were 
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resuspended in NB medium supplemented additionally with 2 µg/ml heparin, 20 ng/ml FGF-2 
and 20 ng/ml EGF. Singe cells started to form spheres within one week of suspension culture. 
Cultures were maintained as neurospheres in uncoated culture flasks at 37°C in a humidified 
incubator with 5% CO2. Half of the cell culture medium was changed twice a week, by 
centrifuging the medium containing the neurospheres at 120 x g for 5 min at 4°C and 
thereafter removing the supernatant and resuspending the cells in fresh growth medium150,151. 
Cell cultures were passaged in weekly intervals. Passaging of neurospheres was performed as 
follows: the medium containing the neurospheres was collected in a 15 ml centrifuge tube and 
centrifuged at 120 g x 5 min at 4°C. The cell-pellet was resuspended in 200 µl of AccutaseTM 
and incubated at 37°C for 10 min. The neurospheres were resuspended in growth medium and 
triturated. Viable cells were counted by trypan blue exclusion assay in a Neubauer 
hemocytometer and a total number of 5 x 104 cells/ml was seeded in T75 culture flasks in 
fresh growth medium. To label cells, NPC were genetically modified to express the reporter 
gene GFP as described46. Briefly, NPC were plated in sub-confluent  
densities (10.000 cells/cm2) on P-Ornithin/Laminin-coated cell culture flasks. The cells were 
incubated for 8 hours on two consecutive days with retrovirus containing supernatants 
(pCLE-GFP or pLXSNGFP) supplemented with 1 µg/ml Polybrene. Approximately 60% of 
all cells displayed GFP fluorescence 2 days following the transduction. To select for GFP-
expressing cells that integrated the retroviral vector, G418 (500 µg/ml active concentration) 
was added to the growth medium for 6 weeks. This concentration has previously been 
determined to completely eliminate all untransfected NPC within 3 weeks. Successful 
incorporation of the transgene into all NPC was confirmed by an inverted fluorescence 
microscope (Olympus, Germany). Following G418 selection, cells were cultivated in the 
absence of G418.  
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3.2.2.2. Preparation of fibroblasts (FF) 
Primary cultures of adult Fischer 344 fibroblasts were generated from skin biopsies and 
cultivated under standard culture conditions as previously described130,152. A small skin 
biopsy was taken after the fur over the abdominal region was shaved. The biopsy was put into 
70% ethanol for a few seconds, washed in Hank´s balanced salt solution and fat tissue was 
removed. The biopsy was then cut into small pieces (1 x 1 mm) and transferred in culture 
wells containing Dulbecco’s minimal essential medium (DMEM) supplemented with 2 mM 
L-glutamine, 100 U/ml penicillin / 0.1 mg/l streptomycin, 3.5 mg/ml Glucose and 10% fetal 
bovine serum. The medium was changed twice a week. When cells reached 90% confluence, 
they were passaged by trypsinization (0.25% Trypsin). After counting an aliquot of the 
resulting single cell suspension in a Neubauer hemocytometer, 5 x 104 cells/ml were plated in 
fresh medium. 
 
3.2.2.3. Preparation of mesenchymal stem cells (MSC) 
MSC were isolated from bone marrow plugs harvested from femurs and tibias of Fischer 344 
rats (2-4 months old). Plugs were mechanically dissociated in alpha minimum essential 
medium (αMEM) and recovered by centrifugation. Cell pellets were resuspended in αMEM 
containing 10% fetal bovine serum (αMEM-10% FBS) and seeded at  
a density of 1x106 cells/cm2 in a humidified incubator at 37°C with 5% CO2. After 3 days 
medium was changed and non-adherent cells were removed. Adherent cells were incubated in 
fresh αMEM-10% FBS until a confluent layer of cells was reached. These cells were 
trypsinized using 0.25% Trypsin and seeded in αMEM-10% FBS at 8.000 cells/cm2.  
After 3-5 days of culture, the resulting monolayer of cells, hereafter named rat bone marrow-
derived MSC, was trypsinized and frozen or cultured for further experiments. As 
demonstrated previously, this cell culture preparation is highly enriched with multipotent 
MSC containing virtually no hematopoietic contamination147.  
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3.2.2.4. Preparation and use of conditioned media 
For preparation of the MSC-CM and fibroblast-conditioned medium (FF-CM), each cell type 
was plated at 12.000 cells/cm2 and incubated in αMEM-10% FBS. After 3 days, MSC-CM 
and FF-CM were collected and filtered using a 0.22 µm pore filter.  
 
3.2.2.5. In vitro differentiation assays 
NPC were plated on polyornithine (100 µg/ml) and laminin (5 µg/ml)-coated glass coverslips 
at a concentration of 5.000 cells/ml in α-MEM–10% FBS for 12-24 hours. Thereafter the 
medium was replaced with MSC-CM or FF-CM. NPC, which were kept in  
α-MEM–10% FBS medium served as controls. After 7 days cells were fixed for 30 minutes 
with phosphate-buffered 4% (wt/vol) paraformaldehyde (37°C, pH 7.4) and then processed 
for immunocytochemistry. 
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3.2.3. Immunocytochemistry 
Fixed cells were washed in Tris-buffered saline (TBS) (0.15 M NaCl, 0.1 M Tris-HCl, 
pH=7.5), then blocked with a solution composed of TBS, 0.1% Triton X-100 (only for 
intracellular antigens), 1% bovine serum albumin (BSA) and 0.2% fishskin gelatine  
buffer (FSGB). The latter solution was used for the following incubation steps with 
antibodies. Primary antibodies were applied over night at 4°C. Fluorochrome-conjugated 
species-specific secondary antibodies were used for visualization. 
The following primary antibodies and final concentrations have been used: rabbit anti-glial 
fibrillary acidic protein (GFAP) for astroglia (1:1000), mouse anti-myelin basic protein 
(MBP) (1:750; SMI-94) for oligodendroglia and mouse anti-microtubule associated  
protein 2ab (Map2ab) (1:250) for neurons. Goat anti-green fluorescent protein (GFP) (1:500) 
was used to detect GFP-positive NPC. Secondary antibodies: donkey anti-mouse, -rabbit or  
-goat conjugated with rhodamine X (RHOX) (1:500) or Alexa fluor 488 (1:1000). Nuclear 
staining was performed with 4’,6’-diamidino-2-phenylindole-dihydrochloride-hydrate (DAPI) 
at 0.25 µg/µl. Coverslips were mounted on microscope slides using Prolong Antifade. 
Epifluorescence observations and photodocumentations were realized using a Leica 
fluorescent microscope (Leica, Wetzlar, Germany) equipped with a Spot CCD camera  
model 2.2.1 (Diagnostic Instruments, Inc., Sterling Heights, USA). 
For each culture condition randomly selected observation fields, containing five hundred  
to 1.000 GFP-positive cells, were photographed for cell fate analysis. The expression 
frequency of selected cell type markers was determined for every condition in three 
independent experiments. 
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3.2.4. Preparation of respective cell types for transplantation 
For transplantation, MSC and FF were trypsinized. A sample of single cell suspension was 
stained with Trypan Blue and counted in a Neubauer Hemocytometer. The remaining single 
cell suspension was washed twice and resuspended in PBS to yield a final concentration  
of 0.6x105 cells/µl. 
 
3.2.5. Surgical procedures 
For all surgical procedures animals were anaesthetized using a cocktail of ketamine, xylazine 
and acepromazine as described above.  
 
3.2.5.1. Cervical dorsal column transection 
Lesioning of the dorsal columns was performed using a tungsten wire knife (Kopf 
Instruments, Tujunga, USA) to transect the dorsal columns bilaterally, thereby interrupting 
the dorsal component of the corticospinal projection and a portion of the rostrally projecting 
proprioceptive dorsal sensory pathway. Rats were fixed in a spinal stereotactic unit (Kopf 
Instruments, Tujunga, CA), skin and muscles were incised and a laminectomy was performed 
at C3 level. A small dura incision was made. For C3 lesions, the tungsten wire knife was 
stereotactically positioned 0.6 mm to the left of midline and lowered to a depth of 1.1 mm (for 
illustration see Figure 1). The tip of the wire was extruded from the device, 
forming a 2.25 mm-wide wire arch, that was then raised 2 mm to lesion the corticospinal tract 
(CST) bilaterally. To ensure complete interruption (rather than strechting) of corticospinal 
axons, a 500 µm-wide glass pipette was tightly compressed against the wire loop under 
microscopic guidance. 
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A large proportion of the overlying dorsal funicular sensory ascending projection was also 
lesioned by the procedure. Afterwards the wire arch was retracted back into the knife device 
and the instrument was removed from the spinal cord. This lesion is highly localized and 
reproducible, permitting precise characterization of local responses to injury and associations 
of defined axonal populations to the injury milieu46,153,154. 
 
3.2.5.2. Cell transplantation into the injured spinal cord 
After stereotactically guided transection of the dorsal CST with a tungsten wire knife at 
cervical level C3, a total volume of 2 µl cell suspension containing a) 0.6x105 MSC/µl  
(MSC, n=6 for each timepoint) or b) 0.6x105 fibroblasts/µl (FF, n=6 for each timepoint) was 
injected directly into the lesion site through a pulled glass micropipette (100 µm internal 
diameter) using a Picospritzer Π (General Valve, Fairfield, USA). Animals receiving spinal 
Figure 1: Schematic representation of the Cervical dorsal column transection model 
The crossed dorsal components of CST axons of rats contain about 95% of the descending axons, whereas an 
ipsilateral ventral component contains less than 5% of all CST axons. (A) In this SCI model, a dura incision 
is made and the wire knife device is stereotactically lowered into the spinal cord parenchyma. At the correct 
depth, the tungsten wire is extruded, forming a wire arch below the dorsal component of the corticospinal 
projections. (B) Afterwards, the wire knife device is rised up until the tip of the wire is visible, transecting 
the dorsal columns bilaterally and interrupting the dorsal component of the corticospinal projections and a 
portion of the rostrally projecting proprioceptive dorsal sensory pathway. The wire arch is then retracted back 
into the wire knife device, and the instrument is removed from the cord, thereby leaving the dura intact.  
(C) Directly following the lesion, cell-grafts can be injected under stereotactic guidance into the lesioned area 
through a pulled glass micropipette.  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cord lesions without cell transplantation (Lesion, n=6 for each timepoint) served as controls. 
The lesion/implantation site was covered with gelfoam (Gelita Tampon; Braun, Germany) 
before readapting muscular layers and stapling the skin above the lesion site. 
 
3.2.6. BrdU-injection and experimental design of the in vivo studies 
A short course of daily BrdU-injection (50 mg/kg) was done intraperitoneally (i.p.) starting 
immediately after surgery until day 3 post-op. Animals were perfused on day 3 (2 hours after 
last BrdU-injection) to study endogenous cell proliferation (early timepoint). To determine 
survival of newborn cells derived from endogenous NPC, BrdU (50 mg/kg) was administered 
daily i.p. from day 3-10 post-op before animals were sacrificed on day 28 (late timepoint). 
For illustration see Figure 2. 
 
 
Figure 2: Schematic representation of the experimental design 
All animals received a cervical wire knife dorsal column transection. Early time-point: Animals received 
BrdU injections intraperitoneally once a day on 4 consecutive days, starting right after the surgery. Perfusion 
of the rats was performed on post-op day 3. Late time-point: Rats received BrdU injections once a day for 8 
consecutive days, starting on post-op day 3. Animals were perfused 4 weeks postoperatively.  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3.2.7. Histology 
At 3 or 28 days postoperatively, animals were transcardially perfused with 0.9% saline 
solution for 10 min followed by 4% paraformaldehyde in 0.1 M phosphate buffer for 15 min. 
Spinal cords were dissected, post fixed overnight in 4% paraformaldehyde and cryoprotected 
in PBS containing 30% sucrose at 4°C. A 9 mm block of the cervical spinal cord containing 
the lesion center was divided into three equidistant consecutive levels termed rostral (RO), 
lesion center (LC), and caudal (CA), which were cut into 40 µm thick coronal cryostat 
sections. Three sections (one from each level) with a distance of 3 mm between each other 
were processed for immunohistochemistry (for illustration see Figure 3). Every seventh 
section was collected for Nissl staining to exactly determine the lesion/injection site and to 
assess the overall neuropathological changes (cystic lesion defect, tissue loss, hemorrhage). 
Sections mounted onto gelatine-coated coverslips were hydrated in a downward ethanol series 
starting with a 1:2 chloroform/ethanol mixture. Coverslips were incubated consecutively  
for 2 min each in ethanol 100%, 95%, 70% and 40% and for 5 min in distilled water. For the 
actual staining procedure coverslips were incubated in a thionine-solution for 30 seconds. 
After several rinses in distilled water coverslips were dehydrated consecutively for 2 min each 
in ethanol 40%, 70%, 80% and 95%. Finally, coverslips were incubated for 5 min in 
NeoClear and coverslipped with NeoMount. 
All other sections were stored in 25% glycerol, 25% ethylene glycol and 50% 0.1 M sodium 
phosphate solution at 4°C. 
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3.2.8. Immunhistochemistry 
3.2.8.1. Brightfield analysis 
Visualization of BrdU incorporating cells with 3,3´diaminobenzidine (DAB) was processed as 
follows: to detect BrdU-labeled nuclei the following DNA denaturation steps preceded the 
incubation with a BrdU specific antibody: after rinsing in TBS, free-floating sections were 
incubated in 0.6% H2O2 for 30 min, washed again and incubated for 1h  
in 50% formamide/2xSSC (0.3 M NaCl, 0.03 M sodium citrate) at 65°C. Sections were rinsed 
Figure 3: Schematic representation of the morphological analysis of endogenous NPC in the injured 
spinal cord 
A 9 mm long piece of the spinal cord was cut into 40 µm thick coronal sections. Three levels (lesion center 
(LC), rostral (RO) and caudal (CA)) with a distance of 3 mm between each other were quantified. Within 
each level one field of view was quantified in up to seven different regions: 1.) central canal (CC), 2.) grey 
matter / white matter transition zone (GM/WM), 3.) corticospinal tract (CST), 4.) ascending tract (AT),  
5.) grey matter (GM), 6.) lateral column white matter (LCWM) and 7.) dorsal root entry zone (DREZ). For 
quantification of the BrdU-DAB staining, all seven regions were analyzed, whereas only the first four regions 
(CC, GM/WM, CST and AT) were analyzed for the fluorescence staining. The red area indicates the lesion 
site. 
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in 2xSSC, incubated for 30 min in 2 M HCl at 37°C and rinsed for 10 min in 0.1 M boric acid 
(pH 8.5). After rinsing in TBS, sections were blocked with a solution composed of TBS,  
0.2% fish skin gelatine, 1% bovine serum albumin and 0.1% Trinton X-100 (only for 
intracellular antigens) for 1h. This buffer was also used during incubation with the  
rat anti-BrdU (1:500) primary antibody over night at 4°C. For chromogenic immunodetection, 
sections were washed extensively and further incubated with a biotin-conjugated species-
specific secondary antibody, donkey anti-rat biotin conjugated (1:500), followed by a 
peroxidase-avidin complex solution from the Vectastain Elite ABC kit. Sections were 
developed in TBS containing 0.25 mg/ml 3,3´diaminobenzidine (DAB), 0.01% (v/v) H2O2, 
and 0.04% /w/v NiCl2. Sections were mounted on gelatine-coated slides, air-dried, dehydrated 
and coverslipped with Neo-Mount.  
 
3.2.8.2. Fluorescence analysis 
Triple labeling immunfluorescence techniques were performed with free floating sections to 
assess the differentiation pattern of endogenous NPC in vivo. Sections were washed in TBS, 
blocked with a solution of TBS, 3% donkey serum and 0.1% Triton X-100 (only for 
intracellular antigens) for 1h and afterwards incubated with the primary antibodies overnight 
at 4°C on a rotating platform. For detection of BrdU-labeled nuclei, the following DNA 
denaturation steps preceded the incubation with rat anti-BrdU antibody: after rinsing in TBS, 
sections were incubated for 1h in 50% formamide/2xSSC (0.3 M NaCl, 0.03 M sodium 
citrate) at 65°C. Sections were rinsed in 2xSSC, incubated for 30 min in 2 M HCl at 37°C and 
rinsed for 10 min in 0.1 M boric acid (pH 8.5).  
The following primary antibodies were used: rat anti-BrdU (1:500) to label newly created 
cells, rabbit anti-GFAP for astroglia (1:1000) and mouse anti-Adenomatous polyposis coli 
(APC) for oligodendrocytes (1:500). The following day, sections were rinsed and incubated 
with fluorescein (donkey anti-mouse IgG Alexa Fluor 488, 1:1000), rhodamine X (donkey 
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anti-rat RHOX, 1:500) and Cy5 (donkey anti-rabbit CY5, 1:500) conjugated donkey 
secondary antibodies for 2h. After a final rinsing step in TBS, sections were mounted onto 
glass slides and coverslipped with Prolong Antifade. 
 
3.2.9. Microscopical analysis  
Brightfield micrographs of DAB-stained sections were obtained with a Leica fluorescence 
microscope (Leica, Wetzlar, Germany) connected to a Spot CCD camera model 2.2.1 
(Diagnostic Instruments, Sterling Heights, USA). Quantitative analysis of BrdU-DAB labeled 
cells was performed using a 40x objective lens. BrdU-immunoreactive nuclei were counted in 
one section out of each spinal cord level (RO, LC or CA) with a distance of 3mm between 
each level. Within each section BrdU-immunoreactive nuclei were quantified in up to seven 
different regions in one field of view (see Figure 3): central canal (CC), grey/white matter 
transition zone (GM/WM), corticospinal tract (CST), ascending tract (AT), grey matter (GM), 
lateral column white matter (LCWM) and dorsal root entry zone (DREZ). Graphs are 
expressed as the total number of cells detected in all seven regions and in all three sections. 
Immunhistochemical analysis was performed using a Leica confocal fluorescence 
microscope TCS-NT (Leica, Wetzlar, Germany) equipped with a 40x PL APO oil objective 
(1.25 numeric aperture). Co-localization of BrdU-labeled cells with the individual 
differentiation markers was determined by analyzing between 30-35 adjacent optical sections 
through the z-axis of 40µm thick coronal sections. Co-localization was confirmed, once the 
differentiation marker was spatially associated to BrdU nuclear labeling through subsequent 
optical sections in the z-axis.  
The in vivo differentiation pattern of endogenous spinal cord NPC was quantified in three 
sections from 3 different levels of spinal cord: LC, RO and CA. Within each section co-
localization of differentiation markers with BrdU was quantified in one field of view out of 4 
different regions (for illustration see Figure 3):  CC, GM/WM, CST and AT. The total 
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number of BrdU positive cells in each field of view was counted and correlated to the number 
of BrdU positive cells co-localizing with the respective differentiation marker (GFAP, APC). 
As APC immunoreactivity is present both in oligodendrocytes and a subset of 
astrocytes155,156, only cells immunoreactive for BrdU and APC - not for GFAP - were 
classified as oligodendroglia. Cells immunorective for BrdU and GFAP were counted as 
astroglia. 
 
3.2.10. Statistical analysis 
Statistical analysis of the in vitro experiments was performed using one-way analysis of 
variances (ANOVA) followed by Tukey´s Multiple Comparision Test for multiple group 
comparisons (*, p<0.05; **, p<0.01; ***, p<0.001). The in vivo part was analyzed using 
parametric one-way analysis of variances (ANOVA) and Dunn´s Multiple Comparison Test 
post-hoc (*, p<0.05; **, p<0.01; ***, p<0.001). All data are expressed as mean ± standard 
error of the mean (SEM). Statistical analysis was performed using PRISM4 software 
(GraphPad Software, San Diego, USA). 
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4. RESULTS 
4.1. IN VITRO 
4.1.1. MSC and FF derived soluble factors induce oligodendroglial differentiation in 
NPC in vitro  
As previously shown, either direct co-culture with MSC or incubation with soluble factors 
derived from MSC significantly enhance oligodendroglial differentiation in NPC derived 
from the adult hippocampus and the SVZ138,147,148. To evaluate whether this pro-
oligodendrogliogenic effect is also present in NPC derived from the spinal cord, NPC from 
the hippocampus (HC), the subventricular zone (SVZ) and the spinal cord (SC) were cultured 
in MSC-CM for one week and subsequently analyzed for the differentiation markers GFAP 
and MBP (for illustration see Figure 4A-F). As control groups primary FF-CM was added 
alone or in combination with MSC-CM to NPC cultures. NPC grown with alpha-MEM 10% 
FBS served as control. 
The capacity of MSC-CM and FF-CM to induce the expression of oligodendroglial markers 
in NPC derived from the SVZ, the HC or the SC in comparison to control medium (α-MEM-
10% FBS) was determined in vitro (Figure 4 and 5). Independent of the origin of NPC (SVZ, 
HC, SC) FF-CM was the strongest promoter of MBP expressing cells (74.2% ± 4.0 in SVZ, 
76.6% ± 0.5 in HC and 73.4% ± 3.4 in SC) followed by MSC-CM+FF-CM (55.7% ± 3.2 in 
SVZ, 55.8% ± 1.3 in HC and 54.5% ± 10.4 in SC), MSC-CM (27.9% ± 8.6 in SVZ, 43.6% ± 
12.8 in HC and 50.1% ± 0.9 in SC) and alpha-MEM (2.9% ± 2.5 in SVZ, 4.5% ± 1.4 in HC 
and 2.4% ± 0.9 in SC). At the same time FF-CM reduced the number of GFAP expressing 
cells (6.5% ± 0.1 in SVZ, 7.8% ± 3.2 in HC and 10.7% ± 0.9 in SC) more than  
MSC-CM+FF-CM (20.7% ± 3.3 in SVZ, 25.2% ± 5.4 in HC and 12.8% ± 1.6 in SC), MSC-
CM (44.6% ± 7.4 in SVZ, 58.1% ± 8.1 in HC and 27.5% ± 2.0 in SC) and alpha-MEM 
(80.6% ± 1.8 in SVZ, 80.1% ± 7.2 in HC and 78.0% ± 2.0 in SC).  
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Figure 4: MSC-CM and FF-CM promote oligodendrogenesis of SVZ-, HC- as well as SC-derived NPC 
in vitro 
Example of NPC (SC) expressing MBP (A-C) or GFAP (D-F). The respective marker (A,D) and DAPI 
counterstain (B,E) were overlayed (C,F). Quantitative analysis of MBP/GFAP expression in adult NPC 
derived from the SVZ (G), HC (H) or SC (I) incubated with either MSC-CM, MSC-CM+FF-CM, FF-CM or 
alpha-MEM. Five hundred to 1.000 GFP-positive cells (NPC) were analyzed in randomly chosen fields. 
Experiments were done in triplicate. Scale bar: 25 µm. Averages are expressed with their standard error of 
the mean (SEM). One-way analysis of variances (ANOVA) followed by Tukey´s Multiple Comparision Test 
for multiple group comparisons was used for statistical analysis. * p < 0.05; ** p < 0.01; *** p < 0.001.  
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In summary, FF-CM represents the most effective conditioned medium to promote 
oligodendroglial differentiation (MBP expression) at the expense of astroglial differentiation, 
irrespective of the NPC origin. Unexpectedly, this pro-oligodendrogenic effect was less 
pronounced after incubation of NPC with MSC-CM. 
Figure 5: The origin of NPC does not influence their differentiation potential in vitro 
Quantitative analysis of GFAP (A) and MBP (B) expression in adult NPC derived from the SVZ, HC or SC 
incubated with either MSC-CM, MSC-CM+FF-CM, FF-CM or alpha-MEM. Five hundred to 1.000  
GFP-positive cells (NPC) were analyzed in randomly chosen fields. Experiments were done in triplicate. 
Averages are expressed with their standard error of the mean (SEM). One-Way ANOVA was used for 
statistical analysis. 
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4.2. IN VIVO 
4.2.1. MSC and fibroblast grafts replace the cystic lesion defect in the injured spinal 
cord 
The key question of this study was to determine, whether MSC and FF derived soluble factors 
would be able to induce oligodendroglial differentiation in endogenous NPC after 
transplantation into the injured rat spinal cord. Therefore MSC as well as FF were 
transplanted directly into the lesion site of an acute spinal cord injury. MSC or FF were 
transplanted as cell suspension directly into the lesion site immediately after a cervical dorsal 
column transection. Animals receiving spinal cord lesions without cell transplantation 
(Lesion) served as controls. Four weeks postoperatively, the injury site displayed the typical 
round-triangular lesion shaped cavity in the dorsal half of the spinal cord as described 
previously130 (for illustration see Figure 6).  
 
 
 
Both MSC and FF grafts integrated well into the host parenchyma and replaced the cystic 
lesion defect completely. There were no signs of uncontrolled graft proliferation or tumor 
formation detectable in any of the animals.  
 
Figure 6: Replacement of the cystic lesion defect 
Four weeks following a cervical wire knife dorsal column transection a typical triangular shaped cystic lesion 
defect develops in animals with spinal cord lesion only (A), whereas FF grafts (B) and MSC grafts (C) 
replace the lesion defect completely. A-C: coronal Nissl stained sections, dorsal top; scale bar: 500µm.  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4.2.2. MSC transplantation does not alter the proliferation and survival of newborn cells 
after spinal cord injury 
The experimental design of the in vivo studies was divided into two different time courses in 
order to investigate proliferation (early timepoint) and survival (late timepoint) of newborn 
cells after SCI (see Figure 2).  
In order to examine the proliferation rate of newborn cells within the spinal cord, BrdU was 
administered intraperitoneally once a day for 4 consecutive days, starting right after the 
animals received a dorsal column transection followed by immediate cell transplantation of 
either MSC (MSC) or fibroblasts (FF), whereas animals receiving lesion only served as 
control (Lesion). Three days postoperatively (early timepoint), animals were perfused, 
processed for BrdU-DAB-staining and analyzed thereafter as described above (for illustration 
see Figure 3). Quantitative analysis of BrdU-labeled cells revealed that the number of BrdU-
positive cells was significantly increased in the FF (288.8 ± 38.7) versus MSC (165.8 ± 20.4) 
graft recipients 3 days post-injury (Figure 7A-C, G). 
In order to investigate the survival of newborn cells (late timepoint), animals received 
intraperitoneal BrdU-injections daily starting at day 3 until day 10 postoperatively. Four 
weeks postoperatively BrdU positive cells were quantified. In contrast to the early time point, 
the number of surviving newborn cells was significantly reduced in FF grafts  
(113.0 ± 17.8) compared to MSC grafts (252.2 ± 71.9) and lesion only animals (279.5 ± 49.4). 
This effect was seen in all sections analyzed (RO, LC, CA) as well as in the total of the three 
sections  (Figure 7D-F, H). 
Taken together, MSC transplantation into the injured cervical rat spinal cord did not alter cell 
proliferation and survival of newborn cells, whereas FF grafting decreased survival of 
newborn cells (late timepoint). Furthermore FF transplantation increased the number of 
proliferating cells (early timepoint) compared to MSC grafting but not to lesion only. 
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Figure 7: MSC do not alter the proliferation or survival of endogenous cells after spinal cord injury 
Proliferation (A-C) and survival (D-F) of newborn cells after SCI; Brightfield images of coronal BrdU-DAB 
stained sections of the three differnt groups: Lesion (A,D), FF (B,E) and MSC (C,F); dorsal top;  
scale bar: 100µm. (G, H) Quantitative analysis of BrdU-positive cells at the early (G) respectively late 
timepoint (H). The amount of BrdU positive cells is expressed as total of the three analyzed sections (LC, 
RO, CA). Averages are expressed with their standard error of the mean (SEM). Parametric one-way ANOVA 
(with Dunn´s Multiple Comparison Test post-hoc) was used for statistical analysis; * p < 0.05; ** p < 0.01.  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4.2.3. MSC enhance oligodendroglial differentiation in endogenous NPC already within 
3 days after SCI 
The extent of astro- and oligodendroglial differentiation of cells, which incorporated BrdU 
within 3 days after SCI was investigated with laser confocal microscopy. The co-localization 
of BrdU- and APC- (for oligodendroglial cells) or GFAP-immunoreactivity (for astroglial 
cells) was analyzed (Figure 8) 
Already at the 3-day timepoint MSC grafts increased the number of APC immunoreactive 
cells (BrdU+/APC+/GFAP-) compared to FF grafts and lesion only (MSC 5.2% ± 0.9;  
FF 0.9% ± 0.2; Lesion 1.2% ± 0.2; Figure 8I). Conversely, the number of newborn cells 
expressing GFAP was significantly reduced after MSC transplantation (51.6% ± 1.2) 
compared to the FF transplantation group (59.9% ± 2.1; Figure 8J).  
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Figure 8: Influence of MSC grafting on glial differentiation of endogenous progenitor cells 
The co-localization of (A) BrdU- and (C) APC-immunoreactivity together with the lack of (B) GFAP 
expression indicated oligodendroglial differentiation (MSC group); (D) Overlay A-C; Co-localization of (E) 
BrdU and (F) GFAP with or without (G) APC expression indicated astroglial differentiation (Lesion group); 
(H) Overlay E-G; scale bar: 15µm. 
Quantitative analysis of the expression of neural differentiation markers in endogenous NPC three days 
respectively four weeks after cell grafting. Graphs show the percentage of oligodendroglial- (I,K) and 
astroglial- (J,L) differentiation. The percentages of BrdU positive oligodendrocytes and astrocytes are shown 
as the total number of all regions/sections analyzed. 
Averages are expressed with their standard error of the mean (SEM). Parametric one-way ANOVA (with 
Dunn´s Multiple Comparison Test post-hoc) was used for statistical analysis; * p < 0.05; ** p < 0.01.  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4.2.4. MSC grafts shift the differentiation of endogenous progenitor cells towards 
oligodendroglia four weeks after SCI 
At 4 weeks postoperatively, MSC grafts significantly increased the number of BrdU positive 
cells expressing the oligodendroglial marker APC compared to FF grafts and the lesion only 
group (MSC 7.1% ± 0.5; FF 0.8% ± 0.2; Lesion 1.5% ± 0.2; Figure 8K). Conversely, MSC 
significantly decreased the number of BrdU positive cells expressing GFAP in comparison to 
FF grafts and the lesion only group (MSC 47.3% ± 1.0; FF 58.1% ± 1.0; Lesion 56.7% ± 1.1; 
Figure 8L). Taken together, MSC grafts shifted the differentiation pattern of endogenous NPC 
towards oligodendroglia at the expense of astroglial cells 28 days postoperatively, whereas FF 
grafts failed to recapitulate the pro-oligodendrogenic effect observed in vitro. 
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5. DISCUSSION 
Based on recent findings that oligodendroglial differentiation can be strongly increased in 
vitro by co-cultivating adult NPC with bone-marrow derived MSC or MSC-CM147,148, the aim 
of the present study was to evaluate if this effect can be recapitulated in an in vivo model of 
SCI. Indeed, this study demonstrates that MSC grafted into the acutely injured rat spinal cord 
promote oligodendroglial differentiation in endogenous NPC as prerequisite for enhanced 
remyelination. Over the last years the activation of endogenous progenitor cells emerged as an 
upcoming approach for neural repair157. Since different groups have described an increase of 
endogenous neural stem cell proliferation following SCI98,158-164 the recruitment of this cell 
population and its modulation towards an oligodendroglial fate represents a promising 
strategy for tissue repair and restoration of neurological function.  
The demonstration of an increased number of APC expressing cells after MSC 
transplanation, which identifies mature oligodendroglial differentiation138,156,165-169, is only a 
first step towards structural and functional improvement after spinal cord injury. Above 
enhancement of oligodendrogliogenesis MSC have been attributed beneficial effects on 
remyelination in different animal models of neurological disorders170-172. The next step is to 
proof enhanced remyelination beyond spontaneous remyelination occurring in the injured 
mammalian CNS. Up to date there are very few studies, which clearly show enhanced 
remyelination induced by either boosting endogenous or exogenous (stem cell 
transplantation) oligodendroglial replacement132,173-176. Therefore it is difficult to analyze 
functional recovery, in particular to link the observed functional improvement to the observed 
structural repair – remyelination128. The majority of studies describe moderate improvement 
in locomotor function usually with a semiquantitative locomotor rating score (e.g. the Basso, 
Beattie and Bresnahan (BBB) locomotor scale method)106,177, which is unspecific in terms of 
the structural correlate and questionable in terms of its clinical relevance. Once all these 
preclinical issues are solved the final question is the one regarding the clinical relevance of 
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such a remyelination approach. There is evidence from small animals and human SCI that 
uninjured, but permanently demyelinated axons exist following spinal cord injury. It has yet 
to be demonstrated that successful remyelination of this undefined quantity of axons is 
sufficient to promote meaningful functional improvement in humans. More likely, the 
remyelination promoting capacity of MSC needs to be combined with axon regrowth 
promoting strategies (see below).  
Increased olidgodendrogliogenesis, indicated by APC expression, was already observed 
at 3 days post-injury and consecutive MSC grafting. In vitro and in vivo studies confirm this 
time line. The number of progenitor cells expressing markers for mature oligodendroglia 
(APC, MBP, GalC) is already enhanced at 3 days after exposure to MSC-CM  
in vitro147-149,178. In vivo (spinal cord demyelination model), a shift from immature 
oligodendrocyte precursor cells (NG2+/BrdU+) towards mature oligodendrocytes 
(APC+/BrdU+) between 2 and 7 days after a single shot BrdU administration has been 
described163.  
Paralleling previous in vitro findings147,148 renewal of astroglia expressing GFAP was 
reduced at 4 weeks post-operatively, suggesting that enhanced oligodendroglial replacement 
happens at the expense of astroglial replacement. Studies investigating cell proliferation and 
renewal after SCI found almost exclusively differentiation into astrocytes179-181. 
In contrast to the successful promotion of oligodendroglial replacement from endogenous 
progenitor pools after MSC grafting, shifting of oligodendroglial differentiation failed in a  
co-grafting paradigm with MSC and NPC137,138. Here the host environment after spinal cord 
injury most likely prevented proper oligodendroglial differentiation in grafted NPC. Main 
molecular candidates are bone morphogenetic proteins (BMP) - strong inducers of astroglial 
differentiaton, which are upregulated immediately after SCI182-185. The BMP mediated 
prevention of oligodendroglial differentiation is supported by in vitro findings, where MSC-
CM is not strong enough to override BMP induced astroglial differentiation138. Of course the 
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question arises, why do we observe enhanced oligodendroglial replacement from endogenous 
progenitor pools after MSC grafting, and not a shift of oligodendroglial differentiation after 
MSC/NPC co-grafting? NPC grafts get fully exposed to BMP expressed after SCI at the 
lesion site, whereas endogenous progenitor cells become recruited continuously over time. 
Since BMP become downregulated within 10 days following injury, MSC derived soluble 
factor(s) can exert their pro-oligodendrogenic effects in endogenous progenitor cells 
throughout the subacute phase beyond 10 days post injury.  
These findings once again underline the importance of the local microenvironment at the 
injury site, which influences the fate of stem/progenitor cell grafts. Previous studies confirm 
these findings showing that molecular cues of the host environment rather than the 
predifferentiation of transplanted cells determine the differentiation of grafted stem cells. The 
same batch of a given neural stem/progenitor cell type differentiates into neurons after 
grafting into neurogenic regions such as the hippocampus and exclusively into glial cells after 
grafting into non-neurogenic regions such as the spinal cord46,130,186-188. On the other hand, the 
origin of adult NPC does not affect the glial/neuronal differentiation pattern vitro. This 
supports the notion that NPC can be obtained from various regions of the CNS without 
affecting the yield of cells differentiated into either astroglia, oligodendroglia or neurons. If 
certain differentiation phenotypes are to be maintained after transplantation, in particular local 
cues derived from the host such as BMP need to be addressed.  
MSC grafts did not interfer with cell proliferation, whereas FF grafts increased the 
number of BrdU positive cells within the first few days after SCI. Syngenic cell grafting in 
general can induce a local inflammatory response contributing to the high cell proliferation 
rate. It is concievable that MSC grafts with their anti-inflammatory, immune-modulating189-193 
as well as anti-apoptotic194,195 properties counteract this proliferation of inflammatory cells 
thus reducing cell proliferation directly or indirectly. At 4 weeks postoperatively, the number 
of surviving newborn cells was reduced in the FF group suggesting that the initial stronger 
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inflammatory response led to increased cell death and poor cell survival in the long run. This 
is in contrast to former findings in the brain which showed increased endogenous progenitor 
cell proliferation consecutive to intracerebral/intravenous MSC injection after brain injury196 
as well as MSC grafting after stroke197. These contrary findings may be caused by a somehow 
differing predominant microenvironment conducive to cell proliferation inside the brain 
compared to the spinal cord. In addition it has to be mentioned that no direct comparison can 
be drawn for the present study as the underlying experimental designs significantly differed 
from each other (used animals, injury model, cell graft administration, timecourse of BrdU-
labeling and perfusion).  
Differential effects of MSC-CM in respect to the origin of NPC – HC, SVZ or  
spinal cord – were investigated more closely but did not reveal any differences. This is 
confirmed by a recent report, which did not reveal any differences in terms of neuronal versus 
glial differentiation in adult SVZ or spinal cord derived NPC198. This finding is potentially 
clinically relevant since the accessibility of “donor” regions within the CNS determines, 
whether an autologous adult stem cell based therapy is feasible or not.  
Surprisingly, strong pro-oligodendrogenic effects were also observed in FF-CM. Since MSC 
and FF belong to mesenchymal tissue derived from the mesoderm, it is conceivable that the 
identical soluble factor is responsible for these effects199,200. As the combination of  
MSC-CM and FF-CM did not produce higher numbers of cells displaying oligodendroglial 
differentiation compared to MSC-CM or FF-CM incubation alone, the yet unidentified 
soluble factor(s) might at least in part act on the same signaling pathway138. Alternatively, FF 
produce this factor in higher concentrations or express an additional factor, which also 
supports oligodendroglial fate determination. According to our in vitro data it is conceivable 
that fibroblasts may express this unidentified factor at a higher concentration201 or even 
express additional factors to promote oligodendroglial differentiation. Overall, several 
candidate factors have been investigated previously, which do not have a significant impact 
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on oligodendroglial differentation: fibroblast-growth factor-2 (FGF-2), brain-derived-
neurotrophic-factor (BDNF), vascular endothelian growth factor (VEGF), ciliary-
neurotrophic factor (CNTF), nerve growth factor (NGF), neurotrophin-3 (NT-3), interleukin-6 
(IL-6), insulin-like growth factor-1 (IGF-1), Noggin147-149. Of course, the identification of 
these pro-oligodendrogenic factors(s) will be important to gain further mechanistic insights 
into the process of oligodendroglial differentiation. This may in the end allow to introduce 
factors, which are efficient enough to overcome host derived cues opposing oligodendroglial 
differentiation.  
Besides remyelination as a potential repair mechanism of MSC grafts, MSC grafts have been 
widely investigated in small animal models of SCI. Besides neuroprotective effects after SCI, 
MSC have been described to attenuate glial scar formation202 and to promote axonal 
regeneration135,203-205 with concomitant functional recovery151,170,206,207. MSC grafts replaced 
the cystic lesion defect completely confirming previous reports, which demonstrated long-
term survival and cyst replacement by MSC grafts130,135,138,208. Cyst replacement is a key 
prerequisite for axon regrowth across the lesion site. Furthermore, MSC can be genetically 
modified to overexpress and release growth factors such as BDNF, NGF or NT-3 locally at 
the lesion site to augment axonal growth135,172,209. Recently, the combination of NT-3 
overexpressing MSC and genetic modification of the host spinal cord adjacent to the lesion 
site to create a chemotrophic gradient has been shown to induce axon regrowth across the 
lesion into the target region within the caudal brainstem with reinnervation of previous target 
neurons210. However, restoration of proper nerve conduction could not be detected yet, which 
is most likely due to a lack of myelination of regenerating axons. It is conceivable that effects 
of MSC-CM next to regenerating axons in the host spinal cord might promote remyelination 
and consecutively restored nerve conduction.  
The relevance of regenerative strategies aiming for remyelination to induce functional 
recovery is underscored by two different cell-based therapies, which were translated into 
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phase I clinical trials. In the first approach, embryonic derived stem cells predifferentiated 
into OPC have been shown to promote remyelination and functional improvement in rat SCI 
models176,211. Unfortunately, the respective clinical trial in acute SCI patients was stopped 
after four patients were treated for yet unknown reasons. However, side effects or 
complications of the transplantation procedure were not reported. In another study, fetal 
human brain derived stem cells are investigated in another phase I clinical trial, after 
preclinical studies in rats and mice reported remyelination and functional improvement after 
experimental SCI and demyelination175,212-214. This clinical trial, which started in 2011, is still 
ongoing128. 
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6. CONCLUSION 
Transplantation of MSC into the acute injured spinal cord is sufficient to enhance 
oligodendroglial differentiation of endogenous spinal cord progenitor cells up to one month 
post-injury. Results from the present study and previously published data confirm that 
underyling mechanisms are based on (a) soluble factor(s) secreted by MSC, which create a 
specific microenvironment supporting oligodendrogliogenesis at the lesion site. The 
identification of these pro-oligodendrogenic factors will be important to gain more 
mechanistic insights in the interactions between MSC and the endogenous progenitor cell 
population within the spinal cord to further boost oligodendroglial differentiation and 
eventually remyelination with subsequent functional recovery. Before the translation into 
clinical trial can be considered clear and unequivocal MSC induced remyelination needs to be 
confirmed. Furthermore, functional recovery including neurophysiology (restoration of nerve 
conduction) and behavioral effects (e.g recovery of locomotion) need to be assessed in 
appropriate animal models such as contusion SCI, which show pronounced demyelination and 
resemble the pathophysiology of human SCI as close as possible. 
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7. ABBREVIATIONS 
Alpha-MEM Alpha Minimum Essential Medium 
ANOVA Analysis of Variance 
APC Adenomatous Polyposis Coli 
ASIA American Spinal Injury Association 
AT Ascending Tract 
BDNF Brain Derived Neurotrophic Factor 
BMP Bone-morphogenetic-protein 
BrdU 5´-Bromo-2´-Desoxyuridine 
BSA Bovine Serum Albumin 
CA Caudal 
CC Central Canal 
CNS Central Nervous System 
CNTF Ciliary Neurotrophic Factor  
CPS Cryo Protect Solution 
CSPG Chondroitin Sulfate Proteoglycan(s) 
CST Corticospinal tract 
Cy5 Cyanine 5 
DAB 3,3´-Diaminobenzidine 
DAPI 4,6´-Diamidino-2-phenylindole 
Dk Donkey 
DMEM Dulbecco´s Modified Eagle Medium 
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DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
DPBS Dulbecco´s Phosphate Buffered Saline 
DREZ Dorsal Root Entry Zone 
EGF Epidermal Growth Factor 
eGFP Enhanced Green Fluorescent Protein 
FBS Fetal Bovine Serum 
FF Fibroblast(s) 
FF-CM Fibroblast-Conditioned Medium 
FGF Fibroblast Growth Factor 
FSBG Fish Skin Gelatine Buffer 
GalC Galactocerebroside 
GFAP Glial Fibrillary Acidic Protein 
GFP Green Fluorescent Protein 
GM Grey Matter 
GM/WM Grey Matter/White Matter transition zone 
Gt Goat 
HBSS Hank´s Balanced Salt Solution 
HC Hippocampus 
IGF-1 Insulin-like growth factor-1 
IgG Immunoglobulin, isoform G 
IL-6 Interleukin-6 
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LC Lesion Center 
LCWM Lateral Column White Matter 
MAG Myelin-Associated Glycoprotein 
Map2ab Microtubule Associated Protein 2ab 
MBP Myelin Basic Protein 
Ms Mouse 
MSC Mesenchymal Stem Cell(s) 
MSC-CM Mesenchymal Stem Cell-Conditioned Medium 
NB Neurobasal 
NG2 Chondroitin Sulfate Proteoglycan 
NGF Nerve growth factor 
NPC Neural stem/progenitor cell(s) 
NT Neurotrophin 
OMgp Oligodendrocyte Myelin Glycoprotein 
OPC Oligodendroglial Precursor Cell(s) 
PBS Phosphate Buffered Saline 
PFA Paraformaldehyde 
Rb Rabbit 
Rhox Rhodamine X 
RO Rostral 
Rt Rat 
SC Spinal Cord 
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SCI Spinal Cord Injury 
SEM Standard Error of the Mean 
SVZ Subventricular Zone 
TBS Tris-Buffered Saline 
VEGF Vascular Endothelian Growth Factor 
WM White Matter 
ZNS Zentrales Nervensystem 
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